Northwest Biotherapeutics (NWBO) FCF Margin Growth (5y) (2015 - 2026)
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) FCF Margin Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 108,206.00 |
| Mar 31, 2026 | 309,526.00 |
| Dec 31, 2025 | 30,548.00 |
| Sep 30, 2025 | -229,565.00 |
| Jun 30, 2025 | 37.33 Mn |
| Mar 31, 2025 | -120,276.00 |
| Dec 31, 2024 | -809,098.00 |
| Sep 30, 2024 | -126,389.00 |
| Jun 30, 2024 | -157,356.00 |
| Mar 31, 2024 | -157,606.00 |
| Dec 31, 2023 | -704,840.00 |
| Sep 30, 2023 | -264,126.00 |
| Jun 30, 2023 | -219,208.00 |
| Mar 31, 2023 | 219,788.00 |
| Dec 31, 2022 | 4.44 Mn |
| Sep 30, 2022 | -408,663.00 |
| Jun 30, 2022 | 100,996.00 |
| Mar 31, 2022 | 1.48 Mn |
| Sep 30, 2021 | -864,238.00 |
| Jun 30, 2021 | 808,530.00 |